Disease · MONDO_0016129

eosinophilic gastroenteritis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. eosinophilic gastroenteritis. Diseases, record MONDO_0016129. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0016129

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: eosinophilic gastroenteritis; Open Targets
Open Targets ID: MONDO_0016129; Open Targets
Other names: EGE, eosinophilic enteritis, eosinophilic gastroenterocolitis; Open Targets
Disease Ontology: DOID:4031; Disease Ontology
NCI Thesaurus: C35330; NCI Thesaurus
Orphanet: ORPHA:2070; Orphanet
Highest stage of its drugs: Phase 3, for 2 of its 6 drugs, from ClinicalTrials.gov; Open Targets

Drugs6

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BENRALIZUMAB	CHEMBL1742991	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
CENDAKIMAB	CHEMBL4297864	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
LIRENTELIMAB	CHEMBL4297878	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
OMALIZUMAB	CHEMBL1201589	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
RESLIZUMAB	CHEMBL2107884	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SIROLIMUS	CHEMBL413	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets6

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	1	FK506-binding protein 1A inhibitor	Phase 1	https://conductscience.org/library/genes/2280	Drugs and targets
IGHE	Immunoglobulin heavy constant epsilon	1	Ig epsilon chain C region inhibitor	Phase 2	https://conductscience.org/library/genes/3497	Drugs and targets
IL13	Interleukin-13	1	Interleukin-13 inhibitor	Phase 3	https://conductscience.org/library/genes/3596	Drugs and targets
IL5	Interleukin-5	1	Interleukin-5 inhibitor	Phase 2	https://conductscience.org/library/genes/3567	Drugs and targets
IL5RA	Interleukin-5 receptor subunit alpha	1	Interleukin-5 receptor subunit alpha inhibitor	Phase 3	https://conductscience.org/library/genes/3568	Drugs and targets
SIGLEC8	Sialic acid-binding Ig-like lectin 8	1	Sialic acid-binding Ig-like lectin 8 inhibitor	Phase 2	https://conductscience.org/library/genes/27181	Drugs and targets

Trials6

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03496571	A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis	Phase 2	65	2024-01-17	Eosinophilic Gastritis, Eosinophilic Gastroenteritis	LIRENTELIMAB	Its record names the disease	ClinicalTrials.gov
NCT05214768	A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis	Phase 3	48	2025-09-18	Eosinophilic Gastroenteritis	CENDAKIMAB	Its record names the disease	ClinicalTrials.gov
NCT05251909	Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)	Phase 3	12	2025-07-14	Eosinophilic Gastritis, Eosinophilic Gastroenteritis	BENRALIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00084097	Omalizumab to Treat Eosinophilic Gastroenteritis	Phase 2	30		Gastroenteritis	OMALIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00017862	Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome	Phase 2	10		Hypereosinophilic Syndrome	RESLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01814059	Sirolimus for Eosinophil-Associated Gastrointestinal Disorders	Phase 1	4		Eosinophilic Gastroenteritis, Eosinophilic Esophagitis	SIROLIMUS	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
CC-93538 360 mg QW vs CC-93538 360 QW/Q2W: Induction and Maintenance: Number of Participants With Anti-Drug-Antibody	2 of 20	0 of 12	32	NCT05214768	Trial comparisons
Benralizumab vs Placebo: Proportion of Patients With a Histologic Response at Week 24	5 of 6	0 of 6	12	NCT05251909	Trial comparisons

Papers from its trials5

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38423296	DERIVED	1	PubMed
34089846	DERIVED	1	PubMed
33085861	DERIVED	1	PubMed
21527026	DERIVED	1	PubMed
20004787	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0016129

GET https://conductscience.org/api/diseases/v1/MONDO_0016129/drugs

API reference For AI assistants